Loading
companiesCompany
CG Oncology
CG Oncology developed cretostimogene, the oncolytic virus for early bladder cancer, and is filing for approval in 2026.
Overview
CG Oncology, based in Irvine, California, and listed as CGON, developed cretostimogene grenadenorepvec, an oncolytic virus for early bladder cancer, and is filing for approval in 2026. Its programme spans BOND-003 in BCG-unresponsive carcinoma in situ, PIVOT-006 in intermediate-risk disease and CORE-008 in BCG-naive patients, and the company went public in 2024. OnCo links it to bladder and urothelial cancer, to the cretostimogene drug record, and to the idea of oncolytic viruses that make interleukin-12 only inside the tumour. Whether an intravesical oncolytic virus can become the standard after BCG failure, ahead of gene therapy and IL-15 competitors, is the open question. Cretostimogene has its own page.
Headquarters
Irvine, CA, US
Scorecard
All companies#345of 1244 companies, score 11
- phase 3 +3
- modalities +2
- 24-month regulatory events +2
- registry trials +4
0 approved, 1 in phase 3, 0 earlier, 0 targets, 4 registry studies. Formula on the scorecards page.
Type
Biotech · CGON
Stage
Public
Website
Phase 3Oncolytic adenovirus (intravesical)
Cretostimogene is a virus engineered to multiply only in bladder cancer cells with a broken RB pathway, instilled into the bladder. It cleared carcinoma in situ in 75% of BCG-unresponsive patients.
Similar pages
- TermBCG-unresponsive
Shares BOND-003, Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
- TrialStudy of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Shares Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
- TreatmentNadofaragene firadenovec
Shares Oncolytic viruses that make interleukin-12 only inside the tumour, Bladder & urothelial cancer.
- TechnologyOncolytic viruses
Shares A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT, BOND-003, Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC, Cretostimogene grenadenorepvec.
- TechnologyIntravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)
Shares Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
- CancerNon-muscle-invasive bladder cancer
Shares A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT, Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC, Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
cancers
fronts
drugs
Phase 3Oncolytic adenovirus (intravesical)